FRA:MRK - Merck KGaA Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started €96.52 +0.12 (+0.12 %) (As of 12/14/2018 04:00 PM ET)Previous Close€96.52Today's Range€95.50 - €97.2652-Week Range€76.60 - €115.00Volume419,943 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company also has collaboration with the Solvias to offer the PyroMAT system, a MAT kit for pyrogen detection; Immutep Limited; Leap Therapeutics, Inc.; and Pfizer Inc. In addition, MERCK Kommanditgesellschaft auf Aktien has a clinical research collaboration with Daiichi Sankyo Company, Limited to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft. Receive MRK News and Ratings via Email Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange FRA Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolFRA:MRK Previous Symbol CUSIPN/A Webwww.merckgroup.com Phone+49-6151-720 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees54,756 Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Merck KGaA (FRA:MRK) Frequently Asked Questions What is Merck KGaA's stock symbol? Merck KGaA trades on the FRA under the ticker symbol "MRK." What price target have analysts set for MRK? 21 brokers have issued 12-month target prices for Merck KGaA's shares. Their forecasts range from €78.00 to €115.00. On average, they anticipate Merck KGaA's share price to reach €98.45 in the next twelve months. This suggests a possible upside of 2.0% from the stock's current price. View Analyst Price Targets for Merck KGaA. What is the consensus analysts' recommendation for Merck KGaA? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 2 sell ratings, 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merck KGaA. Has Merck KGaA been receiving favorable news coverage? News articles about MRK stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck KGaA earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the healthcare company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Merck KGaA's key competitors? Some companies that are related to Merck KGaA include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF), Cipher Pharmaceuticals (CPH) and Cosmos (COSM). Who are Merck KGaA's key executives? Merck KGaA's management team includes the folowing people: Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 61)Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 50)Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 53)Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 47)Ms. Belén Garijo López, CEO of Healthcare & Member of the Exec. Board (Age 58) What is Merck KGaA's stock price today? One share of MRK stock can currently be purchased for approximately €96.52. What is Merck KGaA's official website? The official website for Merck KGaA is https://www.merckgroup.com/. How can I contact Merck KGaA? Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720. MarketBeat Community Rating for Merck KGaA (FRA MRK)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 720 (Vote Outperform)Underperform Votes: 793 (Vote Underperform)Total Votes: 1,513MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: Why do company’s buyback their stock?